Quizartinib Improves Survival in Patients with FLT3-ITD mutated R R AML: QuANTUM-R trial from flt3 itd mutation positive Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Presented by Mark J. Levis, MD, PhD nnDr. Levis presents results of the QuANTUM-R trial, the first positive phase 3 trial to demonstrate improved OS with single-agent quizartinib in the R/R FLT3-ITD AML setting compared with salvage chemotherapy. The data confirm the safety and efficacy of quizartinib and the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor.
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)